#1 NEUROPATHY Program (Pain Relief+Balance+Cognitive)

Sprovato® Depression Program

The Sprovato® Depression Program delivers comprehensive, turnkey mental health solutions designed for today’s primary care and specialty practices. Each program begins with psychological screening and assessment tests that are reimbursable and seamlessly integrated into the workflow, ensuring early detection and proper documentation. From there, patients can access advanced, FDA-approved therapy with Spravato® (esketamine) nasal spray for treatment-resistant depression.

By combining Spravato®, evidence-based treatments, standardized screening, and compassionate care, the program offers personalized solutions for complex behavioral health challenges. Our turnkey approach makes it simple for practices to launch, manage, and sustain services while helping patients connect with qualified psychiatric providers when needed.

Hope, Backed by Science

A psych/behavioral screener is required to confirm depression severity and medical necessity for Spravato® therapy.

Spravato® (esketamine) is an FDA-approved, CMS-reimbursement ready nasal spray used under clinical supervision for adults with treatment-resistant depression or major depression with suicidal thoughts.

Spravato® Works When Antidepressants Don’t

Spravato® is an FDA-approved, CMS-reimbursement ready therapy for adults with major depressive disorder. It is indicated for two patient populations:

Treatment-Resistant Depression (TRD): Adults who have not achieved adequate response after trials of at least two different antidepressants in their current episode.
Major Depressive Disorder (MDD) with Suicidal Ideation or Behavior: Adults experiencing acute suicidal thoughts or behavior, where rapid symptom relief is clinically necessary.

Spravato® is administered as a nasal spray in certified outpatient settings, under direct supervision, with patients observed for at least two hours post-dose to ensure safety. Each visit also includes psychological assessments, providing both clinical oversight and CMS-recognized reimbursement. By incorporating Spravato® into practice, providers gain access to a proven, evidence-based treatment option that delivers rapid symptom reduction, supports long-term outcomes, and integrates seamlessly with existing care models.

Proven Effectiveness: Backed by multiple clinical trials, Spravato demonstrates significant and sustained improvement in depressive symptoms, including rapid relief within 24 hours for many patients.
Supervised & Monitored: Administered in a certified clinic setting with direct observation for two hours post-dose to ensure safety and effectiveness.
Convenience for Patients: Dosing is scheduled twice weekly for the first four weeks, then reduced to weekly or every other week for maintenance, making long-term treatment manageable.

Restoring Balance, Restoring Life.

Features of Spravato® (Esketamine) Therapy

FDA-Approved Innovation: Spravato® is the first FDA-approved nasal spray for treatment-resistant depression and major depression with suicidal thoughts.
Supervised Patient Care: Administered in a certified outpatient clinic, with patients monitored for at least two hours post-dose for safety.
CMS-Reimbursement Ready: Therapy includes psychological testing at every visit, ensuring compliance, proper documentation, and additional reimbursement opportunities.
Seamless Practice Integration: Spravato® protocols and workflow can be implemented with minimal disruption, supported by staff training and CMS-aligned billing guidance.

Benefits for Your Medical Practice

Expand Treatment Options
Spravato® (esketamine) therapy enables you to offer an FDA-approved, next-generation solution for adults with treatment-resistant depression (TRD) or major depressive disorder (MDD) with suicidal thoughts. Combined with reimbursement ready psych tests for screening and ongoing monitoring, your practice can provide a complete, evidence-based care pathway.
Attract New Patients
Spravato® is in high demand among patients and referring providers who are seeking effective alternatives after traditional antidepressants have failed. Offering this therapy positions your practice as a leader in mental health innovation while expanding patient volume.
Boost Revenue Potential
Spravato® treatments are reimbursable by Medicare and most major commercial insurance plans. When combined with monthly reimbursable psych assessments, this creates a sustainable revenue stream while ensuring ongoing documentation of medical necessity.
Comprehensive Training and Support
Spravato® manufacturers and program partners provide turnkey implementation, including REMS certification guidance, staff training, patient education resources, and ongoing clinical and technical support—so your team is equipped for success from day one.

Turnkey Depression Program for Your Patients

Consolidating your care and investing in Spravato® (esketamine) therapy offers a transformative opportunity to enhance your practice, improve patient outcomes, and position your clinic as a leader in the evolving landscape of mental health care. Spravato® therapy provides a cutting-edge, non-invasive solution for patients with treatment-resistant conditions, meeting the growing demand for innovative and effective care options.

Psychological Testing at Every Visit
Each visit includes standardized, CMS-reimbursement ready reimbursable psych testing for depression—ensuring accurate monitoring, documenting medical necessity, and guiding treatment decisions over time.

By choosing to invest in Spravato® therapy, you are investing in the future of your practice and the well-being of your patients. We are here for you every step of the way, ensuring your journey toward offering TMS therapy is as rewarding and impactful as the therapy itself.

Schedule Below to Learn More

Page updated

Report abuse